PSA, a kallikrein-like serine protease glycoprotein encoded by the KLK3 gene, was approved by the FDA in 1986 as a prognostic biomarker in PC and then in 1994 as a diagnostic tool for PC detection among asymptomatic men. The gene discussed is KLK3; the disease is pachyonychia congenita.